Search research articles
Contact Us
Filters
Showing results (1-10 of 358) with videos related to
Page
of 36
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 10, 2017
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma
Catherine Thieblemont
Bulletin Du Cancer
|
June 30, 2015
[Ibrutinib: A new drug of B-cell malignancies]
Catherine Thieblemont
Hematology. American Society of Hematology. Education Program
|
November 24, 2005
Clinical presentation and management of marginal zone lymphomas
Catherine Thieblemont
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2007
Lymphoma in older patients
Catherine Thieblemont, Bertrand Coiffier
International Journal of Hematology
|
January 7, 2003
Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma
Catherine Thieblemont, Bertrand Coiffier
Blood
|
March 23, 2013
MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?
Catherine Thieblemont, Josette Brière
Bulletin Du Cancer
|
February 3, 2021
[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor]
Adrien Rousseau, Catherine Thieblemont
Best Practice & Research. Clinical Haematology
|
March 15, 2017
Clinical aspects and therapy of gastrointestinal MALT lymphoma
Catherine Thieblemont, Emanuele Zucca
La Revue Du Praticien
|
March 14, 2012
[The risk of lymphoma in Sjögren's syndrome]
Catherine Thieblemont, Lionel Galicier
Current Oncology Reports
|
August 15, 2009
Second-line treatment paradigms for diffuse large B-cell lymphomas
Catherine Thieblemont, Christian Gisselbrecht
Page
of 36
Search research articles
Search
Showing results (1-10 of 358) with videos related to
Sort By:
Page
of 36
Hematology. American Society of Hematology. Education Program
|
December 10, 2017
Improved biological insight and influence on management in indolent lymphoma. Talk 3: update on nodal and splenic marginal zone lymphoma
Catherine Thieblemont
Bulletin Du Cancer
|
June 30, 2015
[Ibrutinib: A new drug of B-cell malignancies]
Catherine Thieblemont
Hematology. American Society of Hematology. Education Program
|
November 24, 2005
Clinical presentation and management of marginal zone lymphomas
Catherine Thieblemont
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 10, 2007
Lymphoma in older patients
Catherine Thieblemont, Bertrand Coiffier
International Journal of Hematology
|
January 7, 2003
Combination of chemotherapy and monoclonal antibodies for the treatment of lymphoma
Catherine Thieblemont, Bertrand Coiffier
Blood
|
March 23, 2013
MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?
Catherine Thieblemont, Josette Brière
Bulletin Du Cancer
|
February 3, 2021
[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor]
Adrien Rousseau, Catherine Thieblemont
Best Practice & Research. Clinical Haematology
|
March 15, 2017
Clinical aspects and therapy of gastrointestinal MALT lymphoma
Catherine Thieblemont, Emanuele Zucca
La Revue Du Praticien
|
March 14, 2012
[The risk of lymphoma in Sjögren's syndrome]
Catherine Thieblemont, Lionel Galicier
Current Oncology Reports
|
August 15, 2009
Second-line treatment paradigms for diffuse large B-cell lymphomas
Catherine Thieblemont, Christian Gisselbrecht
Page
of 36